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Senescence is a distinct cellular response induced by DNA-damaging agents and other sublethal stressors and may provide novel
benefits in cancer therapy. However, in an ageing model, senescent fibroblasts were found to stimulate the proliferation of cocultured
cells. To address whether senescence induction in cancer cells using chemotherapy induces similar effects, we used GFP-labelled
prostate cancer cell lines and monitored their proliferation in the presence of proliferating or doxorubicin-induced senescent cancer
cells in vitro and in vivo. Here, we show that the presence of senescent cancer cells increased the proliferation of cocultured cells
in vitro through paracrine signalling factors, but this proliferative effect was significantly less than that seen with senescent fibroblasts.
In vivo, senescent cancer cells failed to increase the establishment, growth or proliferation of LNCaP and DU145 xenografts in nude
mice. Senescent cells persisted as long as 5 weeks in tumours. Our results demonstrate that although drug-induced senescent cancer
cells stimulate the proliferation of bystander cells in vitro, this does not significantly alter the growth of tumours in vivo. Coupled with
clinical observations, these data suggest that the proliferative bystander effects of senescent cancer cells are negligible and support the
further development of senescence induction as therapy.
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Senescence is a physiological programme of terminal growth
arrest occurring in both normal and immortalised cells in response
to telomeric alterations, and also to sublethal stress and
inappropriate oncogenic signalling. Senescent cells develop a
characteristic phenotype, including an enlarged, flattened morpho-
logy, prominent nucleus, senescence-associated heterochromatin
foci (SAHF), and senescence-associated b-galactosidase (SAb-gal)
activity (Narita et al, 2003; Campisi, 2005; Lee et al, 2006).
Cancer treatments, including radiation and chemotherapy, induce
senescent characteristics in cells. Doxorubicin and cisplatin
are more efficient in generating senescence in cell culture
than ionising radiation, etoposide or the microtubule-targeting
drugs docetaxel and vincristine (Chang et al, 1999). Heterogeneous
SAb-gal staining has been observed in sections of frozen human
breast tumours after treatment with cyclophosphamide,
doxorubicin and 5-fluorouracil (te Poele et al, 2002), and in
lung tumours, after carboplatin and taxol (Roberson et al, 2005).
Senescence develops at lower drug concentrations than
apoptosis, potentially limiting treatment-related side effects
(Schwarze et al, 2005).
Senescence may provide a number of unique therapeutic
benefits. When senescence is induced by expressing p53 in a
murine liver cancer model, an upregulation of inflammatory
cytokines triggers an innate immune response that targets the
tumour cells (Xue et al, 2007). Other studies have suggested
senescence may function as an alternative mechanism of tumour
inhibition. In mice bearing Em-myc lymphomas, treated with
cyclophosphamide, when apoptosis was blocked by Bcl-2 over-
expression, senescence developed and these animals had improved
survival over the apoptotic tumours (Schmitt et al, 2002). The
recognition that a senescence programme may be reinduced in
immortalised and tumorigenic cells by exposure to selected drugs
presents a putative target for blocking cancer cell growth.
However, senescence induction may potentially promote
tumour growth. Senescent cells express a variety of growth factors
and secreted proteins that may stimulate as well as inhibit cell
proliferation (Chang et al, 2002; Schwarze et al, 2002, 2005;
Untergasser et al, 2002; Bavik et al, 2006). In contrast to apoptosis,
a programme of cellular destruction, senescent cells persist and
remain viable. SAb-gal activity in cells has been putatively
identified in ageing tissues, including skin and benign prostatic
hyperplasia specimens (Dimri et al, 1995; Choi et al, 2000).
Consistent with the hypothesis that ageing induces a procarcino-
genic environment, fibroblasts passaged to replicative senescence
induce the proliferation of local bystander cells both in vitro and in
xenografts (Krtolica et al, 2001; Bavik et al, 2006). To determine
whether senescent cancer cells generate a bystander effect or not,
we chemically induced senescence in prostate cancer cells using
doxorubicin and examined their effect on a bystander cancer cells
in vitro and in vivo.
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Cell lines and cell culture
DU145 and LNCaP prostate cancer cell lines, and human primary
fibroblasts, were cultured and senescence induced by treatment
with 25nM doxorubicin as described previously (Schwarze et al,
2005). Polyclonal green fluorescence protein (GFP)
(þ) cell lines
were generated by infecting DU145 and LNCaP cells with pLS-GFP
virus and repeated sorting of GFP
(þ) cells. Resulting cell lines
stably express GFP in B98 and B80% of DU145- and LNCaP-
derived cell lines, respectively. GFP
(þ) cells in both lines were
approximately 100  brighter than non-labelled cells, as measured
by flow cytometry (data not shown).
Cell-counting experiments
For coculture experiments, 50000 DU145 or 200000 LNCaP
GFP
(þ) tagged cells and equivalent proliferating or senescent
untagged cells or 50000 senescent primary prostate fibroblasts
were plated together in triplicate in 35-mm wells containing
growth medium. The following day, cells were washed twice in
phosphate-buffered saline (PBS), given minimal medium (50%
F12/50% DMEMþpenicillin/streptomycin) and returned to 371C,
5% CO2. Cells were collected after 2 or 4 additional days in culture.
Cell viability in counted samples was determined by annexinV
binding (Invitrogen, Carlsbad, CA, USA) and by propidium iodide
exclusion. Data were acquired from samples by flow cytometry and
analysed using WinMDI v2.8 software (Joseph Trotter, Scripps
Research Institute) to calculate the total number of viable GFP
(þ)
cells in each sample.
Counting experiments were repeated using threefold the number
of proliferating or senescent cells (from 50000 to 150000 cells), or
a decreased fraction of senescent cocultured cells (75 and 25%
senescent vs proliferating), incubated in minimal medium for 4
days and analysed as above.
BrdU incorporation
In cell-counting experiments (above), 20mM BrdU was added to
cell-culture medium, 30min prior to trypsinisation, and GFP
(þ)
cells were recovered by fluorescence-activated cell sorting. Isolated
cells were fixed in 100% ethanol and stored at  201C.
Subsequently, cells were rehydrated and stained for BrdU as
described previously (Krtolica et al, 2001; Schwarze et al, 2003).
BrdU incorporation of cells cocultured in transwells did not
require cell sorting.
Xenograft cocultures
All animal protocols and studies were conducted in accordance
with the guidelines of the Association for Assessment and
Accreditation of Laboratory Animal Care International, and
approval was obtained from the University of Wisconsin Institu-
tional Animal Care and Use Committee. Male athymic nude mice
were obtained from Harlan (Madison, WI, USA). Xenograft
tumours were established as described previously (Passaniti
et al, 1992a,b). DU145-GFP
(þ) and unlabelled proliferating or
senescent DU145 cells (0.5 10
6, each) were injected into the
mouse subinguinal fat pad and allowed to develop into xenograft
tumours over 5 weeks time. Tumour dimensions were measured at
3, 4 and 5 weeks after injection using a caliper. BrdU was injected
into these mice interperitoneally at a concentration of 70mgkg
 1
body weight (Christov et al, 1993), harvested 2h later and
dissociated into a single-cell suspension from which GFP
(þ) cells
were isolated by fluorescence-activated cell sorting. These were
fixed in ice-cold ethanol and stored at  201C. BrdU incorporation
was measured in recovered cells, as mentioned above.
LNCaP xenografts were established by injecting 1 10
6 LNCaP
cells alone, with 50% Matrigel (BD Biosciences, San Jose, CA, USA)
or with an equal number of senescent LNCaP cells as described
(Passaniti et al, 1992a,b), and cells were measured as mentioned
above. Additionally, xenografts were established using 0.5 10
6
DU145 cells with or without addition of equal number of senescent
GFP
(þ)-DU145 cells. Tumours were measured as mentioned
above, harvested at 3 and 5 weeks and samples were frozen in
OCT for sectioning.
Immunofluorescence staining and microscopy
Ten micrometre sections of xenografts were fixed in PBSþ4%
paraformaldehyde/0.2% Triton X-100/10mM NaF/1mM Na3VO4
and washed in PBSþ0.2% Triton X-100/10mM NaF/1mM Na3VO4
(wash buffer) before incubation in blocking buffer (wash buffer þ
10% fetal bovine serum þ1% bovine serum albumin) for 1h at
room temperature. Sections were washed in blocking buffer and
incubated with 1mgml
 1 anti-IGF2 as a cellular counterstain
(1:200 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA; no. sc-5622) overnight at 41C. Sections were again washed,
incubated for 1h with 200ngml
 1 (1:1000 dilution) anti-rabbit-
Alexa 594þ10ngml
 1 Hoechst 33342 (Invitrogen), washed and
mounted using ProLong Gold (Invitrogen). Images were captured
using an Olympus microscope with mercury lamp, appropriate
filters and spot digital camera and imaging software (Diagnostic
Instruments Inc., Sterling Heights, MI, USA). Images were merged
and visualised using NIH ImageJ (http://rsb.info.nih.gov/ij/).
Statistical methods
Data were analysed, standard deviation and standard error were
calculated, and Student’s t-tests were performed using Microsoft
Excel. Error bars in all figures represent one standard deviation in
the data.
RESULTS
We generated stable GFP-expressing lines of the hormone-
refractory DU145 (p53-inactive) and the androgen-dependent
LNCaP (expressing functional p53) prostate cancer cell lines. To
monitor the bystander effect of chemically induced senescent
cancer cells, GFP
(þ) cells were cocultured with proliferating or
senescent unlabelled cancer cells, collected and analysed by flow
cytometry. Both DU145 and LNCaP cells treated with low-dose
(25nM) doxorubicin for 3 days develop a senescent phenotype,
increased SAb-gal staining (Figure 1A), and express previously
described senescence marker genes (Schwarze et al, 2005).
Initially, DU145-GFP
(þ) or LNCaP-GFP
(þ) cells were plated
with equal numbers of proliferating or doxorubicin-induced
senescent untagged cells and cultured in a minimal serum-free
medium for 2 and 4 days. GFP
(þ) cells cocultured with senescent
cells were similar in number to those cocultured with proliferating
cells at 2 days (Figure 1B). However, after 4 days, a significant
increase in DU145 (1.46 fold; Po0.0001) and LNCaP (1.51 fold;
P¼0.022) cells was observed when cocultured with senescent cells.
Apoptosis of GFP
(þ) cells, measured by annexin-V binding and
propidium iodide exclusion at each time point, was not
significantly affected by the presence of senescent cells (o1% in
each sample), suggesting that these observed differences were not
due to effects on cell survival. Proliferation, measured by BrdU
incorporation, was also increased at day 4 (16–21%; P¼0.003) in
GFP
(þ) DU145 cells, exposed to senescent cells (Figure 1C). When
DU145 and LNCaP cells were cocultured in 0.4m transwell inserts,
preventing contact between the two populations but allowing
exposure to common media, BrdU incorporation was similarly
increased (20–24%; Po0.0001 and Po0.05, respectively). Given
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experiments performed on single plates suggested the majority of
the growth stimulation observed was induced by secreted soluble
factors.
Increasing the numbers of cocultured proliferating and senes-
cent cells threefold in both DU145 and LNCaP cells (150000 cells)
sustained this proliferative response (1.4-fold; in both DU145 and
LNCaP cells P¼0.03 and P¼0.003, respectively; data not shown)
demonstrating that this effect was not an artifact of media
depletion. Decreasing the fraction of cocultured senescent cells to
38 and 12% of the total cell population (decrease of 25 and 75% in
the unlabelled senescent cells) did not induce proliferation (data
not shown). These results demonstrate that a proliferative
bystander effect can be stimulated in vitro by chemically induced
senescent prostate cancer cells through paracrine signalling.
Previously published data have demonstrated a significant
proliferative response of bystander cells to senescent fibroblast
lines (Krtolica et al, 2001; Bavik et al, 2006). Therefore, we
compared the proliferative bystander response of senescent DU145
cells to three replicatively senescent prostate fibroblast lines
generated through prolonged passage in cell culture (Figure 2A).
Senescent fibroblasts demonstrated SA-b gal staining and senes-
cent morphology. After 4 days in coculture, the increase in the
number of prostate cancer cells exposed to senescent fibroblasts
was twice that seen with senescent cancer cells (60 vs 30%,
respectively; Po0.01). We then confirmed the induction (42 fold)
of a number of growth-promoting paracrine factors in our
chemically induced senescent DU145 and LNCaP cells
(Figure 2B) using qPCR. No increase in expression of these genes
(IGF2, BRAK, FGF11 and Wnt5a) was seen in the senescent
fibroblast lines. Comparing growth-promoting gene expression
data from a number of studies involving fibroblasts, epithelial cells
and cancer cells (Schwarze et al, 2005; Bavik et al, 2006) reveals
little overlap when fibroblasts are compared to other cell lines
(Figure 2B). In sum, our data show that senescent fibroblasts
induce the proliferation of bystander cells in vitro significantly
more than senescent prostate cancer cells.
Next, we investigated whether senescent cancer cells
promote the growth of non-senescent cancer cells in nude mouse
tumour xenograft models or not. LNCaP prostate cancer
xenografts require additional growth factors, provided by
Matrigelt, to establish viable tumours and proliferate (Passaniti
et al, 1992a,b). To determine if senescence has a similarly
permissive effect on xenograft tumour establishment, mice were
injected with 1 10
6 LNCaP cells either alone, with 50% Matrigel
or with 1 10
6 senescent LNCaP cells (n¼5 in each group).
Six weeks after injection, LNCaP cells coinjected with Matrigel
developed into viable tumours in all five animals. In contrast,
tumours did not develop under the other conditions (0/10 mice).
This demonstrates that chemically induced senescent LNCaP
cells do not promote tumour establishment and/or growth of this
cell line.
Untreated
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Figure 1 Proliferative bystander effect of drug-induced senescent prostate cancer cells in vitro.( A) Bright-field images of DU145 cells cultured on cover
slips ±25nM doxorubicin (DOX) for 3 days, fixed and stained for SA b-gal activity (400 ). (B) Number of proliferating DU145-GFP
(þ)or LNCaP-GFP
(þ)
cells after coculture with proliferating or senescent non-tagged cancer cells measured by flow cytometry. Replicate results were averaged from four
independent experiments. These results represent the average fold increase of cell numbers in senescent cocultures relative to proliferative cell data. Error
bars represent standard error (*Po0.0001; **P¼0.022). (C) BrdUþ incorporation in cells after direct coculture (left) and in transwells (right) after 30min
incubation with 20uM BrdU. The results of three independent experiments were averaged and the numbers of cells from senescent cocultures were
normalised to that of proliferating cocultures. Error bars represent standard error (*P¼0.003, **Po0.0001).
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growth in DU145 xenografts using two different approaches. First,
we coinjected 0.5 10
6 DU145-GFP
(þ) proliferating cells with an
equal number of unlabelled proliferating or senescent DU145 cells
(1 10
6 total) to model the effects of treatment-induced senes-
cence in 50% of tumour cells. Tumours were palpable in both
groups after 2 weeks and tumour dimensions were measured 3, 4
and 5 weeks after injection. The average volume of tumours
established with or without senescent cells was calculated for each
time point. Reflecting the greater number of proliferating
cells initially injected, xenografts containing only proliferating
cells grew significantly larger than those containing senescent cells
after 5 weeks (Po0.001) (Figure 3A, left). However, the average
exponential rate of tumour growth was not significantly affected by
the presence of senescent cells, illustrated by calculating the
natural log (ln) of the average tumour volume over time
(Figure 3A, right). Control animals, in which only senescent cells
were injected, did not develop palpable tumours through the
course of these experiments. Mice were injected with 70mgkg
 1
body weight BrdU 2h prior to tumour harvest to measure
proliferation in sorted GFP
(þ) tumour cells (Christov et al,
1993). Cells from DU145 tumours established with or without
senescent cells and collected after 5 weeks contain similar fractions
of proliferating cells as measured by BrdU uptake and DNA
profiling (data not shown). As a second approach, we repeated this
experiment by beginning with equivalent numbers (0.5 10
6)o f
proliferating DU145 cells and determining the effect of adding
additional (0.5 10
6) senescent cells. Again, the presence of
senescent cells did not increase average tumour size or the rate
of tumour growth (Figure 3B left, right).
Using senescent GFP
(þ)-DU145 cells in this second approach
allowed us to determine whether senescent cells persisted through
the growth of these tumours or not. GFP
(þ) senescent cells were
detected in xenograft tumours harvested 3 and 5 weeks after
injection. However, at these time points, senescent cells were found
infrequently (1–4 cells per section; mean 1 hpf; Figure 3C). SA
b-gal analysis of tumour sections demonstrated infrequently
stained cells, confirming these findings (data not shown). These
results demonstrate that non-proliferating senescent cells become
diluted during xenograft growth, yet persist even 5 weeks after
injection. Therefore, the presence of chemically senescent cancer
cells does not increase the rate of xenograft tumour establishment
or growth in vivo.
DISCUSSION
Significant interest has been generated regarding the role of
senescence as a tumour suppressor and the clinical ramifications
of its reactivation in cancer (Schmitt et al, 2002; Petti et al, 2006;
Xue et al, 2007). Potential exists for development of therapeutic
compounds that specifically induce senescence in cancer cells
(Roninson, 2003). However, concerns have been raised regarding
the promoting effect of senescent cancer cells on the tumour
microenvironment, similar to that seen with senescent fibroblasts
(Kahlem et al, 2004). Our results demonstrate that a limited
proliferative response occurs in vitro with chemically induced
senescent cells when compared to senescent fibroblasts
(Figure 2A). However, this bystander effect does not affect
xenograft tumour establishment or the growth of non-senescent
bystander tumour cells in vivo (Figure 3).
Using multiple cell types and combinations, senescent cells did
not impact in vivo tumour growth or proliferation. When
xenografts were established using proliferating cells with and
without senescent cells, tumours were consistently smaller in the
presence of senescent cells (Figure 3B). We acknowledge that a
transient increase in proliferation may be induced prior to the
development of a palpable tumour, but clearly, the long-term
impact on tumour size was not significant. Technically similar
mixing experiments in immune-deficient mice have been per-
formed using senescent fibroblasts and a stimulatory effect was
easily demonstrated using multiple immortalised and tumorigenic
cell lines (Krtolica et al, 2001; Parrinello et al, 2005; Bavik et al,
2006). In vivo, these studies utilised equivalent numbers of
proliferating and senescent cells similar to our methods. Our data
clearly show the lack of a stimulatory response when senescent
cancer cells are mixed with proliferating cancer cells in tumours.
Furthermore, with current chemotherapy regimens, senescent cells
appear at a much lower frequency (o20%) than those tested in our
experiments (te Poele et al, 2002; Roberson et al, 2005).
As part of our study, we contrasted, in vitro, the bystander effect
of senescent fibroblasts to that seen with chemically induced
senescent cancer cells. Using our quantitative and reproducible
model, the in vitro proliferative effect of senescent cancer cells was
noted to be 40–50% of that seen with senescent fibroblasts. Our
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Figure 2 Bystander proliferation induced to a greater extent by
replicatively senescent prostate fibroblasts than senescent prostate cancer
cells. (A) Number of proliferating DU145-GFP
(þ) cells cocultured with
proliferating or senescent DU145 cells or three independent primary
prostate fibroblast cell lines after passage to replicative senescence. Data
from all three senescent fibroblast lines were averaged. Results are
expressed relative to proliferating coculture data. Error bars represent
standard error (*Po0.01). Results are representative of two experiments.
(B) Expression of secreted growth factor genes reported in chemically
induced senescent prostate cancer cells and senescent fibroblast
(
1Schwarze et al, 2005 Neoplasia;
2Bavik et al, 2006. Canc. Res. *Increased
gene expression confirmed in senescent cancer cells by quantitative
RT-PCR in the present study).
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show significant variation between growth-promoting genes
expressed by senescent epithelial cells, fibroblasts and cancer cells
(Chang et al, 2002; Schwarze et al, 2002, 2005; Untergasser et al,
2002; Zhang et al, 2003; Bavik et al, 2006). The finding that gene
expression perturbations during senescence differ greatly between
fibroblasts and epithelial cells, but show physical clustering on
DNA, has been thought to reflect the altered chromatin structure
seen during senescence (Zhang et al, 2003). These changes are
likely to be even more marked in cancer cells containing deletions,
duplications and distorted nuclear structure.
In vivo, the expression of secreted extracellular matrix, growth
factors and surface receptor proteins differs markedly from cells
cultured in vitro (Gieseg et al, 2004). This disparity in the tumour
microenvironment may contribute to the lack of induction of
proliferation in response to senescent cells in vivo. As an example,
IGF2 protein expression is clearly elevated in senescent cancer cells
in vitro, but the expression of IGF2 protein does not quantitatively
differ in vivo, when senescent and proliferating cells are compared
(data not shown). A unique aspect of our study is the
demonstration of a persistence of senescent cells in tumours as
long as 5 weeks after injection. They represent a small population
at this time point, less than 1%, due to expansion of the
proliferating population, which doubles in roughly 48h (Passaniti
et al, 1992a,b). Senescent cells have been noted in the skin of
elderly individuals (Dimri et al, 1995) and in melanocytic naevi
(Michaloglou et al, 2005). Our data in a xenograft model would
support the persistence of these cells in various organs.
Placing senescence induction in the context of cancer treatment,
our results suggest that the specific induction of senescence in
prostate tumour cells would not promote tumour growth.
Accumulating data suggest that senescent cells may occur in vivo
after the treatment of tumours with chemotherapy, in approxi-
mately 40% of breast tumours after treatment using a CAF regimen
(te Poele et al, 2002). Other observations support that senescence
in vivo is a beneficial phenotype by inducing a cellular immune
response (Petti et al, 2006; Xue et al, 2007) and demonstrating a
survival advantage when compared to solely apoptotic responses
(Schmitt et al, 2002). Recently, senescent cells were identified in
human melanocytic nevi, a benign, stable skin lesion, supporting
its function as a long-term tumour-suppressive mechanism
(Michaloglou et al, 2005). In this case, there are no apparent
signs of enhanced bystander proliferation or increased local
carcinogenesis. Staining for senescent cells has also been identified
in benign prostatic hyperplasia tissues, a common benign entity
not associated with cancer (Choi et al, 2000). In conclusion, our
data demonstrate that the presence of chemically senescent
prostate cancer cells does not significantly enhance the growth of
tumour xenografts, providing further rationale for the develop-
ment of anticancer strategies that efficiently induce senescence in
advanced cancers.
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xenograft tumours established using DU145-GFP
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6) mixed with an equal number proliferating (ProþPro) or senescent (ProþSen) cells
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